Literature DB >> 16518966

Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity.

Christine A Jansen1, Erwan Piriou, Iris M De Cuyper, Karel van Dort, Joep M A Lange, Frank Miedema, Debbie van Baarle.   

Abstract

In this study we investigated the long-term effect of highly active antiretroviral therapy (HAART) on HIV-specific CD4+ T-cell responses in comparison with virus-specific CD4+ T-cell responses against the persistent herpes viruses cytomegalovirus (CMV) and Epstein-Barr virus (EBV). To this end, HIV- and herpes virus-specific cellular immune responses were measured longitudinally in 10 seroconverters with long-term follow-up including 55 months of successful suppression of viral load by HAART. HIV- and CMV-specific CD4+ T cells producing interferon-gamma (IFNgamma) or interleukin-2 (IL-2) were analysed as well as proliferative capacity. EBV-specific CD4+ T cells were determined using a 12-day ex vivo assay. Initiation of HAART resulted in a transient increase of HIV-specific IL-2(+)IFNgamma(+)CD4(+) T cells and, to a lesser extent, IL-2(+)CD4(+) T cells. Long-term HAART resulted in an increase in HIV-, CMV- and EBV-specific CD4+ T-cell proliferative capacity. The increase in HIV- and herpes-virus-specific CD4+ T-cell proliferative capacity after 55 months of HAART suggests that the improved proliferative response is not specific for HIV, but reflects a more general improvement of antiviral immune responses, which is induced by HAART.

Entities:  

Mesh:

Year:  2006        PMID: 16518966

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  8 in total

1.  Effects of long-term use of antiretroviral therapy on the prevalence of oral Epstein-Barr virus.

Authors:  Korntip Amornthatree; Hutcha Sriplung; Winyou Mitarnun; Wipawee Nittayananta
Journal:  J Oral Pathol Med       Date:  2011-10-08       Impact factor: 4.253

2.  Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study.

Authors:  Cissy Kityo; Stephanie Bousheri; Juliette Akao; Francis Ssali; Rose Byaruhanga; Isaac Ssewanyana; Prossy Muloma; Sula Myalo; Rose Magala; Yichen Lu; Peter Mugyenyi; Huyen Cao
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

Review 3.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

4.  Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Authors:  D E Perez-Mazliah; M G Alvarez; G Cooley; B E Lococo; G Bertocchi; M Petti; M C Albareda; A H Armenti; R L Tarleton; S A Laucella; R Viotti
Journal:  J Antimicrob Chemother       Date:  2012-10-26       Impact factor: 5.790

5.  Do CD4+ T cell functional responses to Epstein-Barr virus provide protective immunity against CNS lymphoma in AIDS?

Authors:  Mark A Jacobson
Journal:  PLoS Med       Date:  2007-03-27       Impact factor: 11.069

6.  γ-Herpesvirus load as surrogate marker of early death in HIV-1 lymphoma patients submitted to high dose chemotherapy and autologous peripheral blood stem cell transplantation.

Authors:  Chiara Pratesi; Stefania Zanussi; Rosamaria Tedeschi; Maria Teresa Bortolin; Renato Talamini; Maurizio Rupolo; Chiara Scaini; Giancarlo Basaglia; Matteo Di Maso; Mario Mazzucato; Ernesto Zanet; Umberto Tirelli; Mariagrazia Michieli; Antonino Carbone; Paolo De Paoli
Journal:  PLoS One       Date:  2015-02-10       Impact factor: 3.240

7.  A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy.

Authors:  Gareth Ad Hardy; Nesrina Imami; Mark R Nelson; Ann K Sullivan; Ron Moss; Marlén Mi Aasa-Chapman; Brian Gazzard; Frances M Gotch
Journal:  J Immune Based Ther Vaccines       Date:  2007-04-11

Review 8.  Immune activation and collateral damage in AIDS pathogenesis.

Authors:  Frank Miedema; Mette D Hazenberg; Kiki Tesselaar; Debbie van Baarle; Rob J de Boer; José A M Borghans
Journal:  Front Immunol       Date:  2013-09-26       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.